Fortuna Fix Inc.

About Fortuna Fix Inc.

Fortuna is a private, clinical-stage biotech company with a patented direct cell reprogramming technology platform together with a patented bio-scaffolding technology for treatment of neurodegenerative diseases and neurotrauma. The company is focused on clinical development of its platforms for a range of neurodegenerative diseases including SCI, Parkinson's disease, stroke, TBI, and ALS. The company has developed a proprietary fully automated GMP manufacturing system for production of drNPC, initially to be used in clinical trials in Parkinson's disease and Spinal Cord Injury.
YEAR FOUNDED:
October 16, 2015
LEADERSHIP:
CEO & CSO: Jan-Eric Wilhelm Ahlfors
CFO & Chief Commercialization Officer
SCIENCE:
Please click here for Fortuna's science.